Comparison of the effects of glibenclamide on metabolic parameters, GLUT1 expression, and liver injury in rats with severe and mild streptozotocin-induced diabetes mellitus

Medicina (Lithuania)

Volumn 48, Issue 10, 2012, Pages 532-543

  Sokolovska, Jelizaveta ^a,b   Isajevs, Sergejs ^a   Sugoka, Olga ^a   Sharipova, Jelena ^b   Paramonova, Natalia ^b   Isajeva, Darja ^a   Rostoka, Evita ^a,b   Sjakste, Tatjana ^a   Kalvinsh, Ivars ^b   Sjakste, Nikolajs ^a,b  

^a UNIVERSITY OF LATVIA   (Latvia)

^b LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

Expression; Glibenclamide; GLUT1; Kidney; Streptozotocin

Indexed keywords

EID: 84875548717     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina48100078     Document Type: Article

References (25)

1. +(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother 2006;50:4214-6.
2. Tsiani E, Ramlal T, Leiter LA, Klip A, Fantus IG. Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 1995;136:2505-12.
3. Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 1996;28:469-87.
4. Wasada T, Yano T, Ohta M, Yui N, Iwamoto Y. ATP-Sensitive potassium channels modulate glucose transport in cultured human skeletal muscle cells. Endocr J 2001;48:369-75.
5. Flores C, Rojas S, Aguayo C, Parodi J, Mann G, Pearson JD, et al. Rapid stimulation of L-arginine transport by Dglucose involves p42/44(mapk) and nitric oxide in human umbilical vein endothelium. Circ Res 2003;92:64-72.
6. Fernandes MA, Santos MS, Moreno AJ, Duburs G, Oliveira CR, Vicente JA. Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. J Biochem Mol Toxicol 2004;18:162-9.
7. Nguyen C, Pan J, Charles MA. Preclinical studies of glimepiride. Drugs Today (Barc) 1998;34:391-400.
8. Sokolovska J, Isajevs S, Sugoka O, Sharipova J, Lauberte L, Svirina D, et al. Correction of glycaemia and GLUT1 level by mildronate in rat streptozotocin diabetes mellitus model. Cell Biochem Funct 2011;29:55-63.
9. Sokolovska J, Isajevs S, Sugoka O, Sharipova J, Lauberte L, Svirina D, et al. Influence of metformin on GLUT1 gene and protein expression in rat streptozotocin diabetes mellitus model. Arch Physiol Biochem 2010;116:137-45.
10. Rakitien N, Rakietien M, Nadkarni MV. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep 1963;29:91-8.
11. Zhang M, Lv XY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008;2008:704045.
12. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds). Bioinformatics methods and protocols: methods in molecular biology. Totowa, NJ: Humana Press; 2000. p. 365-86.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat J, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
14. Imamur H, Morimoto I, Tanaka Y, Hashimoto O, Kanda K, Yamashita S, et al. Regulation of glucose transporter 1 expression by gliclazide in rat L6 myoblasts. Diabetes Nutr Metab 2001;14:308-14.
15. Bähr M, Holtey M, Müller G, Eckel J. Direct stimulation of myocardial glucose transport and glucose transporter-1 (GLUT1) and GLUT4 protein expression by the sulfonylurea glimepiride. Endocrinology 1995;136:2547-53.
16. Cortes P, Riser BL, Asano K, Rodríguez-Barbero A, Narins RG, Yee J. Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Kidney Int 1998;54:1985-98.
17. Brosius FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol 2005;20:447-51.
18. Hwang D-Y, Ismail-Beigi F. Stimulation of GLUT-1 glucose transporter expression in response to hyperosmolarity. Am J Physiol Cell Physiol 2001;281:C1365-72.
19. Bouché C, Serdy S, Kahn CR, Goldfine AB. The cellular fate of glucose and its relevance in type 2 diabetes. Endocrine Reviews 2004;25:807-30.
20. Wasada T, Yano T, Ohta M, Yui N, Iwamoto Y. ATPSensitive potassium channels modulate glucose transport in cultured human skeletal muscle cells. Endocr J 2001;48:369-75.
21. Yan J, Young M, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009;119:2818-28.
22. Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J, et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 2001;50:414-17.
23. Wiggins D, Gibbons GF. The lipolysis/esterification cycle of hepatic triacylglycerol. Its role in the secretion of verylow- density lipoprotein and its response to hormones and sulphonylureas. Biochem J 1992;284:457-62.
24. Broadway NM, Saggerson ED. Inhibition of liver microsomal carnitine acyltransferases by sulphonylurea drugs. FEBS Lett 1995;371:137-39.
25. Giannico G, Cortes P, Baccora MH, Hassett C, Taube DW, Yee J. Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells. Am J Physiol Renal Physiol 2007;292:F57-65.